Clinical outcomes and cost-utility analysis of GKRS plus TKIs versus TKIs in patients with EGFR-mutant lung adenocarcinoma and brain metastases: a Markov decision model
The use of GKRS plus TKIs not only reduces disease recurrence and improves prognosis but also demonstrates a higher level of cost-effectiveness. These findings offer valuable guidelines for clinicians and inform healthcare authorities in optimizing resource allocation for improved medical care.
Authors
- Hon-Yi Shi
- Yu‐Hsien Huang
- Huai‐Che Yang (ORCID: https://orcid.org/0000-0002-4949-5417)
- Songtao Liu (ORCID: https://orcid.org/0000-0003-3114-7163)
- Wei-Lun Huang (ORCID: https://orcid.org/0009-0000-0523-8585)
- Cheng‐Chia Lee (ORCID: https://orcid.org/0000-0003-4691-2913)
- Wen-Yuh Chung
Institutions
- National Sun Yat-sen University (TW)
- National Yang Ming Chiao Tung University (TW)
- Kaohsiung Medical University (TW)
- China Medical University (TW)
- Government of Western Australia Department of Health (AU)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- Tajen University (TW)
- China Medical University Hospital (TW)
- Kaohsiung Veterans General Hospital (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
Publication Details
- Journal
- Journal of neurosurgery
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3171/2024.7.jns24310
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52